Composition for promoting ATP (adenosine triphosphate) generation and improving kidney energy metabolism by activating AMPK / PGC-1alpha pathway as well as preparation method and application of composition

Abstract

The invention provides a composition for promoting ATP (adenosine triphosphate) generation and improving kidney energy metabolism by activating an AMPK / PGC-1alpha pathway. The composition is prepared from the following raw materials in parts by weight: 100 to 400 parts of herba cistanche, 50 to 200 parts of radix astragali seu hedysari, 25 to 100 parts of glycine betaine and 150 to 300 parts of alpha-ketoglutaric acid. The invention further provides a preparation method and application of the composition for improving ATP generation and improving kidney energy metabolism by activating the AMPK / PGC-1alpha pathway. Through combined use of cistanche, astragalus membranaceus, betaine and alpha-ketoglutaric acid, a multi-target synergistic mechanism of AMPK activation, metabolic substrate supplementation and epigenetic regulation is formed, the mitochondrial function and ATP generation of kidney cells are comprehensively improved, the limitation of existing single-component or chemical drugs is broken through, a safer and more efficient intervention strategy is provided for kidney energy metabolism disorders, and the clinical application prospect is broad. The invention provides an innovative solution for renal tubular energy disorder, has dual values of metabolic regulation and kidney protection, and conforms to the development trend of natural medicines. The invention belongs to the technical field of food and health care product processing.

Description

Technical Field

[0001] This invention belongs to the field of food and health product processing technology, and relates to a composition that enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, as well as its preparation method and application. Background Technology

[0002] Chronic kidney disease (CKD) and renal energy metabolism disorders are closely related to impaired mitochondrial function and insufficient ATP production. The AMPK / PGC-1α pathway is a core pathway regulating cellular energy metabolism. Its activation can promote mitochondrial biosynthesis and improve oxidative phosphorylation efficiency, thereby increasing ATP supply.

[0003] Currently, treatments for renal energy metabolism disorders (such as chronic kidney disease and renal tubular injury) have the following limitations: (1) Insufficient activation of the AMPK / PGC-1α pathway: Although existing drugs (such as metformin) can activate the AMPK pathway, they have problems such as poor targeting and low renal bioavailability, and long-term use may cause gastrointestinal side effects.

[0004] (2) Limited effect of single components: Although natural components (such as astragaloside A and cistanche phenylethanol glycoside) can partially activate the AMPK or PGC-1α pathway, they are difficult to optimize mitochondrial metabolic flux and epigenetic regulation at the same time, resulting in insignificant ATP production enhancement effect.

[0005] (3) Insufficient supply of metabolic substrates: Simply relying on AMPK activation cannot solve the problem of insufficient tricarboxylic acid cycle (TCA) metabolites, resulting in low ATP synthesis efficiency.

[0006] (4) Lack of synergistic effects: Existing research focuses on single components or synthetic drugs, and has not yet proposed a natural compound strategy based on the synergistic effect of multiple targets.

[0007] Based on the aforementioned technical challenges, there is an urgent need to develop a natural compound preparation to safely and synergistically activate the AMPK / PGC-1α pathway to enhance ATP production and improve renal energy metabolism. Summary of the Invention

[0008] The purpose of this invention is to provide a composition that enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, as well as its preparation method and application, to solve the technical problems of insufficient AMPK / PGC-1α pathway activation, limited single-component effects, insufficient supply of metabolic substrates, and lack of synergistic effects in existing treatments for renal energy metabolism disorders.

[0009] To solve the above-mentioned technical problems, the technical solution adopted by the present invention is: to provide a composition that enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, comprising the following raw materials in parts by weight: 100-400 parts of Cistanche deserticola, 50-200 parts of Astragalus membranaceus, 25-100 parts of betaine, and 150-300 parts of α-ketoglutarate.

[0010] Preferably, the product also includes excipients, which include any one or a combination of at least two of fillers, flow aids, and wetting agents, and the excipients are in the range of 100 to 2000 parts by weight.

[0011] Preferably, the filler includes any one or a combination of at least two of sorbitol, mannitol, microcrystalline cellulose, powdered cellulose, and resistant dextrin; the flow aid includes silicon dioxide; and the wetting agent includes magnesium stearate or sorbitol solution.

[0012] A second aspect of the present invention provides a method for preparing the composition described above, which enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, comprising the following steps: Cistanche deserticola, Astragalus membranaceus, betaine, and α-ketoglutaric acid were pulverized separately, and then mixed with excipients according to their weight proportions and stirred evenly to obtain the composition.

[0013] Preferably, the particle size is controlled at 80-100 mesh during pulverization; the stirring speed is 20-100 r / min and the stirring time is 5-20 min.

[0014] A third aspect of the present invention provides an application of the composition described above, which enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, for use in the preparation of food or health products that enhance ATP production and improve renal energy metabolism.

[0015] Preferably, the food or health product includes compressed candy, soft candy, soft capsules, hard capsules, solid beverages, and liquid beverages.

[0016] A fourth aspect of the present invention provides the use of the composition described above, which enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, for the preparation of a medicine that enhances ATP production and improves renal energy metabolism.

[0017] Preferably, the medicine includes tablets, capsules, granules, and oral liquids.

[0018] This invention provides a composition that enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, as well as its preparation method and application. Compared with the prior art, the beneficial effects of this invention are: (1) This invention activates the LKB1-AMPK pathway by adding Cistanche deserticola (phenylethanol glycoside) and Astragalus membranaceus (astragaloside A), thereby enhancing mitochondrial function through AMPK phosphorylation; by adding α-ketoglutarate (AKG) as an intermediate in the tricarboxylic acid cycle, it can directly supplement metabolic substrates, solve the bottleneck of insufficient metabolic substrates, and thus indirectly enhance the deacetylation activity of SIRT1 by increasing NAD+ levels; by adding betaine (methyl donor), it can reduce the methylation of the PGC-1α promoter, enhance PGC-1α expression by regulating epigenetic mechanisms, and make up for the short-term effect defects of a single AMPK activator; Cistanche deserticola, Astragalus membranaceus, betaine The combined use of alkaloids, α-ketoglutarate, and other ingredients forms a multi-target synergistic mechanism: ① Cistanche deserticola / Astragalus membranaceus activates upstream AMPK kinases (such as LKB1); ② α-ketoglutarate optimizes mitochondrial metabolic flux; ③ Betaine opens the PGC-1α promoter region through demethylation modification. This forms a multi-target synergistic mechanism of "AMPK activation + metabolic substrate supplementation + epigenetic regulation," comprehensively enhancing renal cell mitochondrial function and ATP production. It overcomes the limitations of existing single-component or chemical drugs, providing a safer and more efficient intervention strategy for renal energy metabolism disorders and an innovative solution for renal tubular energy disorders. It has both metabolic regulation and renal protection value, which is in line with the trend of natural drug development.

[0019] (2) This invention improves the following three aspects by adding Cistanche deserticola, Astragalus membranaceus, betaine, and α-ketoglutarate: ① Significantly activates the AMPK / PGC-1α pathway and enhances mitochondrial function; ② Significantly increases ATP production and improves renal energy supply. AMPK activation promotes glycolipid oxidation, AKG optimizes TCA cycle efficiency, and mitochondrial function recovery reduces cell apoptosis; ③ Improves renal function and reduces oxidative stress. ATP supply recovery improves glomerular filtration and tubular reabsorption, and the AMPK / PGC-1α pathway inhibits ROS generation. The combination of these drugs complements each other and can enhance ATP production and improve renal energy metabolism by activating the AMPK / PGC-1α pathway. The effect is significant, the bioavailability is high, and the drug is efficient, safe, and avoids the side effects of chemical drugs. Detailed Implementation

[0020] To make the technical problems, technical solutions, and beneficial effects to be solved by this application clearer, the following detailed description is provided in conjunction with embodiments. It should be understood that the specific embodiments described herein are merely illustrative of this application and are not intended to limit this application. Unless otherwise specified, the methods used in this invention are conventional methods; the raw materials and apparatus used, unless otherwise specified, are conventional commercially available products.

[0021] To demonstrate the reliability of the effectiveness of the present invention, the present invention will be described below with reference to embodiments and compared with comparative examples.

[0022] Example 1 This embodiment provides a composition that enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, comprising the following ingredients by weight: 400 mg of Cistanche deserticola, 200 mg of Astragalus membranaceus, 100 mg of betaine, 150 mg of α-ketoglutarate, 350 mg of sorbitol, and 24 mg of magnesium stearate.

[0023] This embodiment also provides a method for preparing the above-mentioned composition that enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, including the following steps: Weigh each raw material according to the above-mentioned weight, and pulverize Cistanche deserticola, Astragalus membranaceus, betaine, and α-ketoglutaric acid separately, controlling the particle size to 100 mesh during pulverization; then mix with the excipient sorbitol, stir evenly, and stir at a speed of 60 r / min for 20 min; after stirring evenly, compress into tablets to prepare tablets, thus obtaining the composition, named 1#.

[0024] Example 2 This embodiment provides a composition that enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, comprising the following ingredients by weight: 100mg of Cistanche deserticola, 50mg of Astragalus membranaceus, 25mg of betaine, 150mg of α-ketoglutarate, 125mg of microcrystalline cellulose, 25mg of silicon dioxide, and 25mg of magnesium stearate.

[0025] This embodiment also provides a method for preparing the above-mentioned composition that enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, including the following steps: Weigh each raw material according to the above-mentioned weight, and pulverize Cistanche deserticola, Astragalus membranaceus, betaine, and α-ketoglutaric acid separately, controlling the particle size to 100 mesh during pulverization; then mix with excipients microcrystalline cellulose and silicon dioxide, stir evenly, and stir at a speed of 60 r / min for 20 min; after stirring evenly, fill into capsules to prepare a capsule formulation, which is the composition named 2#.

[0026] Example 3 This embodiment provides a composition that enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, comprising the following ingredients by weight: 200 mg of Cistanche deserticola, 100 mg of Astragalus membranaceus, 50 mg of betaine, 300 mg of α-ketoglutarate, and 850 mg of resistant dextrin.

[0027] This embodiment also provides a method for preparing the above-mentioned composition that enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, including the following steps: Weigh each raw material according to the above-mentioned weight, and pulverize Cistanche deserticola, Astragalus membranaceus, betaine, and α-ketoglutaric acid separately, controlling the particle size to 100 mesh during pulverization; then mix with the excipient resistant dextrin, stir evenly, and stir at a speed of 60 r / min for 20 min; after stirring evenly, prepare granules to obtain the composition, named 3#.

[0028] Example 4 This embodiment provides a composition that enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, comprising the following ingredients by weight: 400 mg of Cistanche deserticola, 200 mg of Astragalus membranaceus, 100 mg of betaine, 200 mg of α-ketoglutarate, 2000 mg of sorbitol solution, and 8100 mg of purified water.

[0029] This embodiment also provides a method for preparing the above-mentioned composition that enhances ATP production and improves renal energy metabolism by activating the AMPK / PGC-1α pathway, including the following steps: Weigh each raw material according to the above-mentioned weight, and pulverize Cistanche deserticola, Astragalus membranaceus, betaine, and α-ketoglutaric acid separately, controlling the particle size to 100 mesh during pulverization; then mix with the excipient sorbitol solution, stir evenly, and stir at a speed of 60 r / min for 20 min; after stirring evenly, prepare an oral liquid to obtain the composition, named 4#.

[0030] Comparative Example 1 The difference between this comparative example and Example 4 is that Cistanche deserticola is not added to the composition. That is, the composition includes the following raw materials by weight: Astragalus membranaceus 200mg, betaine 100mg, α-ketoglutarate 200mg, sorbitol solution 2000mg, and purified water 8100mg. The rest of the operation is the same, and the final composition without Cistanche deserticola is obtained, named 1##.

[0031] Comparative Example 2 The difference between this comparative example and Example 4 is that Astragalus membranaceus was not added to the composition. The composition includes the following raw materials by weight: 400 mg of Cistanche deserticola, 100 mg of betaine, 200 mg of α-ketoglutarate, 2000 mg of sorbitol solution, and 8100 mg of purified water. The rest of the operation is the same, and the final composition without Astragalus membranaceus is obtained, which is named 2##.

[0032] Comparative Example 3 The difference between this comparative example and Example 4 is that betaine is not added to the composition. That is, the composition includes the following raw materials by weight: 400mg of Cistanche deserticola, 200mg of Astragalus membranaceus, 200mg of α-ketoglutarate, 2000mg of sorbitol solution, and 8100mg of purified water. The rest of the operation is the same, and the final composition without betaine is obtained, named 3##.

[0033] Comparative Example 4 The difference between this comparative example and Example 4 is that α-ketoglutarate is not added to the composition. That is, the composition includes the following raw materials by weight: 400mg of Cistanche deserticola, 200mg of Astragalus membranaceus, 100mg of betaine, 2000mg of sorbitol solution, and 8100mg of purified water. The rest of the operation is the same, and the final composition without α-ketoglutarate is obtained, named 4##.

[0034] In Examples 1-4 and Comparative Examples 1-4 above, Cistanche deserticola, Astragalus membranaceus, betaine, α-ketoglutarate, excipients sorbitol, microcrystalline cellulose, silicon dioxide, resistant dextrin, and sorbitol solution are all conventional commercially available products that can be purchased directly from the market.

[0035] In the above Examples 1-4 and Comparative Examples 1-4, the preparation method involves controlling the particle size to 100 mesh during pulverization, the stirring speed to 60 r / min, and the time to 20 min. These are only preferred embodiments. In actual operation, the particle size can be controlled to 80-100 mesh during pulverization, the stirring speed to 20-100 r / min, and the time to 5-20 min. As long as the above parameters are within the specified range, they are acceptable. In actual production, adjustments can be made according to specific circumstances.

[0036] To verify the reliability of the effects of the present invention, the technical effects of the compositions obtained in Examples 1-4 and Comparative Examples 1-4 were tested below.

[0037] Group design is adopted: Blank control group: No induction treatment was received; starch placebo solution was injected / administered by gavage. Experimental groups 1-4: Received induction treatment with inducing agents, injected / gavaged with aqueous solution or oral solution of composition 1#-4#; Control groups 1-4: received induction treatment with an inducing agent and were injected / gavaged with oral solution of composition 1##-4##.

[0038] During testing, the efficacy of the composition of the present invention was tested in accordance with the testing method for improving renal energy metabolism function in the "Technical Specifications for Inspection and Evaluation of Health Foods (2003 Edition)".

[0039] (1) Subject selection ①Inclusion criteria: Mice aged 10-18 months showed chronic fatigue, decreased renal function, or mild renal dysfunction (e.g., eGFR 60-90 mL / min / 1.73 mcg) after induction treatment with the inducer. 2 Mice that have not been given drugs or health supplements that improve energy metabolism or protect kidney function in the past 3 months.

[0040] ② Exclusion criteria: Severe kidney disease (Scr>2.5 mg / dL), diabetic nephropathy stage IV or above, acute kidney injury; Allergic to any of the ingredients in this product; Combined with serious diseases of the heart, liver, and hematopoietic system.

[0041] ③ Sample size: There are 50 animals in each group, and a total of 9 groups.

[0042] (2) Test methods ① Inducer: Adenine.

[0043] ②The test substances are shown in Table 1.

[0044] Table 1. Test substances in the experimental and control groups

[0045] Dosage and administration: Take 2 tablets (1.2g) / 3 capsules (0.5g) / 1 sachet of granules (10g) / 1 bottle of oral liquid (25mL) / 10g starch placebo twice daily for 60 consecutive days.

[0046] (3) Efficacy Judgment Criteria The scores of primary symptoms (lower back and knee pain, weakness, and frequency of nocturia) and secondary symptoms (aversion to cold) of mice in each group before and after administration were observed.

[0047] The primary symptom score (lower back and knee pain, fatigue, and frequent urination at night) and the secondary symptom score (aversion to cold) are scored from 0 to 3 points according to their severity. The specific assessment method is shown in Table 2.

[0048] Table 2 Judgment Method

[0049] In Table 2, "occasional" means 1 to 2 times per day; "frequent" means 1 to 3 times per day; and "frequent" means more than 3 times per day.

[0050] Mice in each group were observed before and after administration. The decrease in total score was calculated based on the scores before and after administration to determine the effectiveness of the test substance. The effectiveness criteria are as follows: Significant effect: Total score reduced by ≥70%; Effective: Total score reduced by ≥30%; Invalid: The above standards are not met.

[0051] Total effective individuals = effective individuals + effective individuals.

[0052] (4) Efficacy evaluation results The improvement rate of the test substance on the four symptoms was determined by statistically analyzing the total number of valid individuals. The formula for calculating the improvement rate is as follows: Improvement rate % = Total effective individuals / Total individuals.

[0053] The improvement rates for the four symptoms are shown in Table 3.

[0054] Table 3 Efficacy Evaluation Results

[0055] As shown in Table 3: As can be seen from test groups 1 to 4, the compositions of Examples 1 to 4 all improved the above symptoms to varying degrees, and the degree of improvement was relatively large; thus, it can be seen that the compositions of Examples 1 to 4 have obvious good effects in improving soreness and weakness of the waist and knees, fatigue, frequent urination at night, and aversion to cold.

[0056] Comparing experimental groups 1-4 with control groups 1-4, it can be seen that the compositions of comparative examples 1-4 are significantly less effective than those of examples 1-4 in improving lower back and knee weakness, fatigue, frequent urination at night, and aversion to cold. This indicates that the absence of any one of Cistanche deserticola, Astragalus membranaceus, betaine, or AKG prevents the combined use of all four from achieving the desired effect in improving lower back and knee weakness, fatigue, frequent urination at night, and aversion to cold. Therefore, the combined use of Cistanche deserticola, Astragalus membranaceus, betaine, and AKG in this invention produces a strong synergistic effect, forming a multi-target synergistic mechanism of "AMPK activation + metabolic substrate supplementation + epigenetic regulation." The combination of these drugs complements each other, enhancing ATP production and improving renal energy metabolism by activating the AMPK / PGC-1α pathway.

[0057] The above experimental results show that after taking the compositions of Examples 1 to 4, the mice experienced significant improvements in symptoms such as lower back and knee pain, weakness, frequent urination at night, and aversion to cold. Therefore, it can be inferred that the compositions of Examples 1 to 4 of this invention have the effect of activating the AMPK / PGC-1α pathway to enhance ATP production and significantly improve renal energy metabolism.

[0058] The present invention also provides the application of the compositions prepared in Examples 1 to 4 that enhance ATP production and improve renal energy metabolism by activating the AMPK / PGC-1α pathway, for use in preparing foods or health products that enhance ATP production and improve renal energy metabolism, including compressed candies, gummies, soft capsules, hard capsules, solid beverages, and liquid beverages.

[0059] The present invention also provides the application of the compositions prepared in Examples 1 to 4 that enhance ATP production and improve renal energy metabolism by activating the AMPK / PGC-1α pathway, for use in the preparation of pharmaceuticals that enhance ATP production and improve renal energy metabolism, including tablets, capsules, granules, and oral liquids.

[0060] In summary, this invention provides a composition for enhancing ATP production and improving renal energy metabolism by activating the AMPK / PGC-1α pathway, its preparation method, and its application. Compared with the prior art: (1) This invention adds Cistanche deserticola (phenylethanol glycoside) and Astragalus membranaceus (astragaloside A), which work together to activate the LKB1-AMPK pathway, thereby enhancing mitochondrial function through AMPK phosphorylation; by adding α-ketoglutarate (AKG) as a tricarboxylic acid cycle intermediate, it can directly supplement metabolic substrates, solve the bottleneck of insufficient metabolic substrates, and thus indirectly enhance the deacetylation activity of SIRT1 by increasing NAD+ levels; by adding betaine (methyl donor), it can reduce the methylation of the PGC-1α promoter and enhance PGC through regulating epigenetic mechanisms. -1α expression compensates for the short-term effect deficiency of single AMPK activators; the combined use of Cistanche deserticola, Astragalus membranaceus, betaine, and α-ketoglutarate forms a multi-target synergistic mechanism: ① Cistanche deserticola / Astragalus membranaceus activates upstream AMPK kinases (such as LKB1); ② α-ketoglutarate optimizes mitochondrial metabolic flux; ③ Betaine opens the PGC-1α promoter region through demethylation modification; thus forming a multi-target synergistic mechanism of "AMPK activation + metabolic substrate supplementation + epigenetic regulation", comprehensively improving renal cell mitochondrial function and ATP production, breaking through the limitations of existing single-component or chemical drugs, providing a safer and more efficient intervention strategy for renal energy metabolism disorders, and providing an innovative solution for renal tubular energy disorders, with dual value of metabolic regulation and renal protection, which is in line with the trend of natural drug development. (2) This invention improves the following three aspects by adding Cistanche deserticola, Astragalus membranaceus, betaine, and α-ketoglutarate: ① Significantly activates the AMPK / PGC-1α pathway and enhances mitochondrial function; ② Significantly increases ATP production and improves renal energy supply. AMPK activation promotes glycolipid oxidation, AKG optimizes TCA cycle efficiency, and mitochondrial function recovery reduces apoptosis; ③ Improves renal function, reduces oxidative stress, restores ATP supply and improves glomerular filtration and tubular reabsorption, and the AMPK / PGC-1α pathway inhibits ROS generation. The combination of these drugs is synergistic, effectively enhancing ATP production and improving renal energy metabolism by activating the AMPK / PGC-1α pathway. The results are significant, with high bioavailability, high efficiency, and safety, avoiding the side effects of chemical drugs. This invention can be widely applied in the fields of food and health product processing technology.

[0061] The above-described embodiments are only used to illustrate the technical solutions of this application, and are not intended to limit them. Although this application has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of this application, and should all be included within the protection scope of this application.

Claims

1. A composition for improving ATP production and renal energy metabolism by activating the AMPK / PGC-1a pathway, characterized by, The composition comprises the following raw materials by weight: 100-400 parts of Cistanche, 50-200 parts of Astragalus, 25-100 parts of betaine, and 150-300 parts of alpha-ketoglutaric acid.

2. The composition for improving ATP generation and renal energy metabolism by activating the AMPK / PGC-1a pathway according to claim 1, wherein, The composition further comprises a filler, a glidant, and a humectant, wherein the filler, the glidant, and the humectant are any one or a combination of at least two of a filler, a glidant, and a humectant, and the weight of the filler, the glidant, and the humectant is 100-2000 parts. 3.The composition for improving ATP generation and renal energy metabolism by activating the AMPK / PGC-1α pathway according to claim 2, characterized in that, The filler comprises any one or a combination of at least two of sorbitol, mannitol, microcrystalline cellulose, powdered cellulose, and resistant dextrin; the glidant comprises silicon dioxide; and the humectant comprises magnesium stearate or sorbitol solution.

4. A method of preparing a composition for improving ATP generation and renal energy metabolism by activating the AMPK / PGC-1α pathway according to claim 1, characterized by, The composition comprises the following steps: The Cistanche, the Astragalus, the betaine, and the alpha-ketoglutaric acid are ground, and then mixed with the filler, the glidant, and the humectant by weight, and stirred uniformly to obtain the composition.

5. The method of claim 4, wherein the composition for improving ATP production and renal energy metabolism by activating the AMPK / PGC-1α pathway is prepared by, The particle size is controlled to be 80-100 mesh during the grinding; and the stirring speed is 20-100 r / min and the stirring time is 5-20 min.

6. Use of a composition for improving ATP production and renal energy metabolism by activating the AMPK / PGC-1α pathway according to claim 1, characterized in that, The composition is used for preparing a food or a health product for improving ATP generation and renal energy metabolism. 7.The use of a composition for improving ATP generation and renal energy metabolism by activating the AMPK / PGC-1α pathway according to claim 6, characterized in that, The food or the health product comprises a tablet candy, a soft candy, a soft capsule, a hard capsule, a solid drink, and a liquid drink.

8. Use of a composition for improving ATP production and renal energy metabolism by activating the AMPK / PGC-1α pathway according to claim 1, characterized in that, The composition is used for preparing a medicine for improving ATP generation and renal energy metabolism. 9.The use of a composition for improving ATP generation and renal energy metabolism by activating the AMPK / PGC-1α pathway according to claim 8, characterized in that, The medicine comprises a tablet, a capsule, a granule, and an oral liquid.

Images